Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 582
Aptamer sequence: GGAGCUCAGCCUUCACUGCAUGAUAAACCGAUGCUGGGCGAUUCUCCUGAAGUAGGGGAAGAGUUGUCAUGUAUGGGGGCACCACGGUCGGAUCCUG
Target unique ID: 6322
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_549 ag.06 Molecule Arginine 330 nM 250 mM NaCl, 50 mM Tris-HCl (pH 7.6), 5 mM MgCl2 8604334
Structure information of aptamer
Aptamer Sequence: GGAGCUCAGCCUUCACUGCAUGAUAAACCGAUGCUGGGCGAUUCUCCUGAAGUAGGGGAAGAGUUGUCAUGUAUGGGGGCACCACGGUCGGAUCCUG
The optimal secondary structure in dot-bracket notation: (((.....(((((((.(((((((((..(((....)))((..((((((((...))))))))..)))))))))))))))))).((......)).)))..
The centroid secondary structure in dot-bracket notation: (((.....(((((((.(((((((((..((......))((..((((((((...))))))))..))))))))))))))))))............)))..
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_549 Description ag.06
Aptamer chemistry RNA Length 97 nt
GC content 55.7% Molecular weight 31,347.58 Da
Molarity of 1 μg/μl solution 31.90 μM Number of G-quadruplexes 2
G-Score 17 Function Aptasensor
Sequence GGAGCUCAGCCUUCACUGCAUGAUAAACCGAUGCUGGGCGAUUCUCCUGAAGUAGGGGAAGAGUUGUCAUGUAUGGGGGCACCACGGUCGGAUCCUG
Applications Detection of arginine
Target information
Type Detail Type Detail
PubChem ID 6322 Molecular name Arginine
Molecular formula C6H14N4O2 Molecular weight 174.2
IUPAC name (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid InChIKey ODKSFYDXXFIFQN-BYPYZUCNSA-N
LogP -1.548 Topological polar surface area 127.72
Hydrogen bond acceptor 3 Hydrogen bond donor 4

Synonym(s):
L-arginine; arginine; 74-79-3; L-(+)-Arginine; L(+)-Arginine; L-Arg; (S)-2-Amino-5-guanidinopentanoic acid; H-Arg-OH; (L)-Arginine; Arginina; ARGININE, L-; Arginine (VAN); L-Arginin; Argininum [INN-Latin]; Arginina [INN-Spanish]; L-Ornithine, N5-(aminoiminomethyl)-; Argamine; Argivene; Detoxargin; Levargin; L-alpha-Amino-delta-guanidinovaleric acid; Minophagen A; 1-Amino-4-guanidovaleric acid; CCRIS 3609; (S)-(+)-arginine; NSC 206269; arg; HSDB 1429; AI3-24165; UNII-94ZLA3W45F; (S)-2-Amino-5-guanidinovaleric acid; BRN 1725413; CHEBI:16467; (S)-2-Amino-5-((aminoiminomethyl)amino)pentanoic acid; L-Norvaline, 5-((aminoiminomethyl)amino)-; MFCD00002635; 2-amino-5-guanidinovaleric acid; CHEMBL1485; (2S)-2-amino-5-guanidinopentanoic acid; (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; 94ZLA3W45F; Pentanoic acid, 2-amino-5-((aminoiminomethyl)amino)-, (S)-; (2S)-2-amino-5-(carbamimidamido)pentanoic acid; L-Arginine, monohydrochloride; Arginine (L-Arginine); R-Gene; L-Norvaline, 5-[(aminoiminomethyl)amino]-; (2S)-2-amino-5-carbamimidamidopentanoic acid; DSSTox_CID_21056; DSSTox_RID_79618; DSSTox_GSID_41056; C6H14N4O2; Argininum; Pentanoic acid, 2-amino-5-[(aminoiminomethyl)amino]-, (S)-; Arginine [USAN:INN]; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid; CAS-74-79-3; Arginine [USP:INN]; EINECS 200-811-1; 2-AMINO-5-GUANIDINO-PENTANOIC ACID; NSC203450; 3h-l-arginine; L-Arginine, labeled with tritium; 1laf; NSC-206269; L-a-Amino-d-guanidinovaleric acid; NCGC00015064-02; (S)-Arginine; L(+) arginine; L-Aryginine,(S); H-Arg; L-(+) arginine; L(+)-Arginine;; L-Arginine (9CI); Arginine (USP/INN); Tocris-0663; (2S)-2-amino-5-guanidino-pentanoic acid; L-Arginine (JP17); GND; Lopac-A-5006; Arginine, L- (8CI); bmse000029; bmse000899; bmse000919; Epitope ID:140084; L-Arginine (H-Arg-OH); EC 200-811-1; SCHEMBL1791; 2-amino-5-guanidinovalerate; Lopac0_000077; Arginine hydrochloride(USAN); GTPL721; 4-04-00-02648 (Beilstein Handbook Reference); L-a-Amino-d-guanidinovalerate; L-Amino-4-guanidovaleric acid; US9138393, L-Arginine; US9144538, L-Arginine; 1-Amino-4-guanidovalerlic acid; DTXSID6041056; BDBM21959; L-Arginine, 99%, FCC, FG; BDBM181132; HMS3260O15; N5-(aminoiminomethyl)-L-Ornithine; HY-N0455; ZINC1532525; L-Arginine, Vetec(TM), 98.5%; Tox21_113046; Tox21_500077; AC-083; L-2-Amino-5-guanidinopentanoic acid; L-alpha-Amino-delta-guanidinovalerate; L-Arginine, reagent grade, >=98%; s5634; AKOS006239069; AKOS015854096; Tox21_113046_1; AM81500; CCG-204172; DB00125; LP00077; MCULE-5108123240; SDCCGSBI-0050065.P002; L-Arginine, 99%, natural, FCC, FG; (s)-2-amino-5-guanidino-pentanoic acid; 5-[(aminoiminomethyl)amino]-L-Norvaline; NCGC00015064-01; NCGC00024715-01; NCGC00024715-02; NCGC00024715-03; NCGC00024715-04; NCGC00024715-05; NCGC00024715-10; NCGC00260762-01; 4455-52-1; AS-14190; K277; L-Arginine, BioUltra, >=99.5% (NT); SBI-0207062.P001; AB0014136; A0526; A7079; EU-0100077; L-Arginine, SAJ special grade, >=98.0%; A 5006; C00062; D02982; L-Arginine, Vetec(TM) reagent grade, >=98%; M02981; 14932-EP2316830A2; 2-azaniumyl-5-(diaminomethyleneammonio)pentanoate; AB00374192_03; Norvaline, 5-[(aminoiminomethyl)amino]-, (L)-; 002A635; A837397; A929348; Q173670; SR-01000075479; SR-01000597671; (S)-2-amino-5-[(aminoiminomethyl)amino]-Pentanoate; (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoate; SR-01000075479-1; SR-01000597671-1; W-104410; (S)-2-amino-5-[(aminoiminomethyl)amino]-Pentanoic acid; Arginine, European Pharmacopoeia (EP) Reference Standard; (2S)-2-amino-5-[(diaminomethylidene)amino]pentanoic acid; 7F15B0C7-356D-45D7-AC33-03AEE4394A0E; S-(+)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; UNII-0O72R8RF8A component ODKSFYDXXFIFQN-BYPYZUCNSA-N; UNII-FL26NTK3EP component ODKSFYDXXFIFQN-BYPYZUCNSA-N; (2S)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid; L-Arginine, United States Pharmacopeia (USP) Reference Standard; L-Arginine, Pharmaceutical Secondary Standard; Certified Reference Material; L-; L-Arginine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%; L-Arginine, PharmaGrade, Ajinomoto, EP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture

Activity data
Interaction ID 582
Target type Molecule
Target unique ID 6322
Activity 330 nM
Binding Conditions/Buffer

250 mM NaCl, 50 mM Tris-HCl (pH 7.6), 5 mM MgCl2

Assay

Affinity elution of ag.06 RNA from an L-arginine column by L-arginine and competition by arginine analogues

PubMed ID 8604334
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_376 RNA GGGAGCUCAGCCUUCACUGCACUCCGGCUGGUGGACGCGGUACGAGCAAUUUGUACCGGAUGGAUGUUCGGGCAGCGGUGUGGCAGGGAUGAGCGGCACCACGGUCGGAUCCAC 66.67%
Apta_936 RNA GGAGCUCAGCCUUCACUGCGAUCACCGUGUCGGUGGCUAGUCGAUGUAUCCCGAUCACCAUUGGGGGCAAGUUUAGACAGGCACCACGGUCGGAUCCAC 65.66%
Apta_256 RNA GGGCGCUAAGUCCUCGCUCAUGCGCGUCCCAUGGGGUAUAGAGGGGUCGAAGUGGACGCGCGACUCGGAUCCU 56.70%
Apta_171 RNA GGGAGCUCAGAAUAAACGCUCAACCAGUCUUGUGGCUUUGAAAGAGAGGAGUGUUCGACAUGAGGCCCGGAUCCGGC 55.67%
Apta_224 RNA GGGGCCACCAACGACAUUGAACCACGUAGGCUCGUUUCUGAGCCGAUCUCGAUGUUGAUAUAAAUAGUGCCCAUGGAUC 54.64%
Apta_696 RNA GAGUGCGCCCAUUGAUAAGAGCGUAGGUUCAACGGAGUCGUAGUCGUUCUCAAGUUGACGGUGCAUUAGAGUCCU 53.61%
Apta_766 RNA GGUUACCAGCCUUCACUGCGGACGGACAGAGAGUGCAACCUGCCGUGCCGCACCACGGUCGGUCACAC 53.61%
Apta_353 RNA GAAUUCCGCGUGUGCCAGCGAAAGUUGCGUAUGGGUCACAUCGCAGGCACAUGUCAUCUGGGCGGUCCGUUCGGGAUCC 52.58%
Apta_575 RNA AGAGCUUGACGGUCCCGAGAGUCGAGCCCAAGCUGACACUGGACCUUUGCGGACCACGUGUUGAUCGUCG 52.58%
Apta_551 RNA GGAUGUCCAGUCGCUUGCAAUGCCCUUUUAGACCCUGAUGAGCGGUGCUAGUUAGUUGCAGUUUCGGUUGUUACGCGAAACGGUGAAAGCCGUAGGUCU 52.53%
Apta_382 RNA GGCGUGACCUGAUGAGUCACGCAGACGCUAGCGAAUUGGUUCCUCGAAAGGGGAAAGCGUUAUUAAGAAACCAAAAUGUGUUACGAAACGUUCCC 51.55%
Apta_383 RNA GGCGUGACCUGAUGAGUCACGCUAAGGAGGAUUUCCGAAAGCGGCUACGGUCCGCCAGUGUUACGAAACGUUCCC 51.55%
Apta_416 RNA GGACCUCGGCGAAAGCCGGUAACGCCACAAGUCGGAGGGUAAGAUCUGACAGGAACUGGGUGACGGAGGUUAGGUGC 51.55%
Apta_566 RNA GGAUAAUAGCCGUAGGUUGCGAAAGCGACCCUGAUGAGCCCUGCGAUGCAGAAAGGUGCUGACGACACAUCGAAACGGUAGCGAGAGCUC 51.55%
Apta_613 RNA GGAUAAUAGCCGUAGGUUGCGAAAGCGACCCUGAUGAGCCUUAGGAUAUGCAUGAUGCAGAAGGACGUCGAAACGGUAGCGAGAGCUC 51.55%
Apta_723 RNA GGGAGCUCAGAAUAAACGCUCAAAUCCGUGGACAGGGCGUAAGCGCCUUCGACAUGAGACACGGAUCCUGCGACGAAUUCAGC 51.55%
Apta_793 RNA GGGAGAGAACAAUGACCUGCGGUGCCAAGCCGUCGGGUUAUGUUGAUCUCCUCAAGGACGAGUGCAUUGCAUCACGUCAGUAG 51.55%
Apta_816 RNA GGGUUCACUGCAGACUUGACGAAGCUUGAGAGAUGCCCCCUGAUGUGCAUUCUUGUUGUGUUGCGGCAAUGGAUCCACAUCUACGAAUUC 51.55%
Apta_559 RNA GGAUGUCCAGUCGCUUGCAAUGCCCUUUUAGACCCUGAUGAGGAUCAUCGGACUUUGUCCUGUGGAGUAAGAUCGCGAAACGGUGAAAGCCGUAGGUCU 51.52%
Apta_280 RNA GAUAAUACGACUCACUAUAGGGUUCACUGCAGACUUGACGAAGCUUGCAGAAAAGGGGGAAGAAGAGGGUGAUUCAGGCGAGAGAAUGGAUCCACAUCUACGAAUUC 51.40%